Differential regulation of TP73 isoforms by 1α,25-dihydroxyvitamin D3 and survivin in human colon and breast carcinomas

Genes Chromosomes and Cancer

Volumn 49, Issue 12, 2010, Pages 1135-1142

  Díaz, Raquel ^a   González Sancho, José M ^b   Soldevilla, Beatriz ^a   Silva, Javier ^a   García, José M ^a   García, Vanesa ^a   Peña, Cristina ^a   Herrera, Mercedes ^a   Gómez, Irene ^a   Bonilla, Félix ^a   Domínguez, Gemma ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b INSTITUTO DE INVESTIGACIONES BIOMÉDICAS ALBERTO SOLS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIRC5 PROTEIN, HUMAN; CALCITRIOL; DNA BINDING PROTEIN; ISOPROTEIN; MESSENGER RNA; MICROTUBULE ASSOCIATED PROTEIN; NUCLEAR PROTEIN; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN P73;

ARTICLE; BIOSYNTHESIS; BREAST TUMOR; COLON TUMOR; DOWN REGULATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; MALE; METABOLISM; PATHOLOGY; POLYMERASE CHAIN REACTION; PROGNOSIS; WESTERN BLOTTING;

BLOTTING, WESTERN; BREAST NEOPLASMS; CALCITRIOL; COLONIC NEOPLASMS; DNA-BINDING PROTEINS; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; NUCLEAR PROTEINS; POLYMERASE CHAIN REACTION; PROGNOSIS; PROTEIN ISOFORMS; RNA, MESSENGER; TUMOR SUPPRESSOR PROTEINS;

EID: 79952200895     PISSN: 10452257     EISSN: 10982264     Source Type: Journal    
DOI: 10.1002/gcc.20821     Document Type: Article

References (48)

1. Abd El-Hameed A. 2005. Survivin expresión in colorectal adenocarcinoma using tissue microarray. J Egypt Natl Canc Inst 17:42-50.
2. Aguilera O, Peñ a C, García JM, Larriba MJ, Ordóñez-Morán P, Navarro D, Barbáchano A, López de Silanes I, Ballestar E, Fraga MF, Esteller M, Gamallo C, Bonilla F, Gonzalez-Sancho JM, Muñoz A. 2007. The Wnt antagonist DICKKOPF-1 gene is induced by 1α,25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells. Carcinogenesis 28:1877-1884.
3. Altieri DC. 2003. Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46-54.
4. Altieri DC. 2006. The case for survivin as a regulator of microtubule dynamics and cell-death decisions. Curr Opin Cell Biol 18:609-615.
5. Altieri DC. 2008. New wirings in the survivin networks. Oncogene 27:6276-6284.
6. Banerjee P, Chatterjee M. 2003. Antiproliferative role of vitamin D and its analogs-A brief overview. Mol Cell Biochem 253:247-254.
7. Becker K, Pancoska P, Concin N, Vanden Heuvel K, Slade N, Fischer M, Chalas E, Moll UM. 2006. Patterns of p73 N-terminal isoform expression and p53 status have prognostic value in gynecological cancers. Int J Oncol 29:889-902.
8. Campbell MJ, Gombart AF, Kwok SH, Park S, Koeffler HP. 2000. The anti-proliferative effects of 1α,25(OH)2D3 on breast and prostate cancer cells are associated with induction of BRCA1 gene expression. Oncogene 19:5091-5097.
9. Concin N, Becker K, Slade N, Erster S, Mueller-Holzner E, Ulmer H, Daxenbichler G, Zeimet A, Zeillinger R, Marth C, Moll UM. 2004. Transdominant DTAp73 isoforms are frequently up-regulated in ovarian cancer. Evidence for their role as epigenetic p53 inhibitors in vivo. Cancer Res 64:2449-2460.
10. Dalhoff K, Dancey J, Astrup L, Skovsgaard T, Hamberg KJ, Lofts FJ, Rosmorduc O, Erlinger S, Bach Hansen J, Steward WP, Skov T, Burcharth F, Evans TR. 2003. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma. Br J Cancer 89:252-257.
11. Deeb KK, Trump DL, Johnson CS. 2007. Vitamin D signalling pathways in cancer: Potential for anticancer therapeutics. Nat Rev Cancer 7:684-700.
12. Demay MB. 2006. Mechanisms of vitamin D receptor action. Ann NY Acad Sci 1068:204-213.
13. Domínguez G, García JM., Peña C, Silva J, García V, Martínez L, Maximiano C, Gómez ME, Rivera JA, García-Andrade C, Bonilla F. 2006. DTAp73 upregulation correlates with poor prognosis in human tumors: Putative in vivo network involving p73 isoforms, p53 and E2F-1. J Clin Oncol 24:805-815.
14. Fillippovich I, Sorokina N, Gatei M, Haupt Y, Hobson K, Moallem E, Spring K, Mould M, McGuckin MA, Lavin MF, Khanna KK. 2001. Transactivation-deficient p73α p73Dexon2 inhibits apoptosis and competes with p53. Oncogene 20:514-522.
15. Freebern WJ, Smith JL, Chaudhry SS, Haggerty CM, Gardner K. 2003. Novel cell-specific and dominant negative anti-apoptotic roles of p73 in transformed leukemia cells. J Biol Chem 278:2249-2255.
16. Fukuda S, Pelus LM. 2006. Survivin, a cancer target with an emerging role in normal adult tissues. Mol Cancer Ther 5:1087-1098.
17. Gombart AF, Luong QT, Koeffler HP. 2006. Vitamin D compounds. Activity against microbes and cancer. Anticancer Res 26:2531-2542.
18. Hansen CM, Binderup L, Hamberg KJ. 2001. Vitamin D and cancer: Effects of 1,25(OH)2D3 and its analogs on growth control and tumorigenesis. Front Biosci 6:D820-D848.
19. Hawker NP, Pennypacker SD, Chang SM, Bikle DD. 2007. Regulation of human epidermal keratinocyte differentiation by the vitamin D receptor and its coactivators DRIP205, SRC2, and SRC3. J Invest Dermatol 127:874-880.
20. Hinnis AR, Luckett JC, Walker RA. 2007. Survivin is an independent predictor of short-term survival in poor prognostic breast cancer patients. Br J Cancer 96:639-645.
21. Jost CA, Marin MC, Kaelin WG Jr. 1997. p73 is a simian [correction of human] p53-related protein that can induce apoptosis. Nature 389:191-194.
22. Kaghad M, Bonnet H, Yang, Creancier L, Biscan JC, Valent A, Minty A, Chalon P, Lelias JM, Dumont X, Ferrar P, McKeon F, Caput D. 1997. Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. Cell 90:809-819.
23. Kawasaki H, Altieri DC, Lu CD, Toyoda M, Tenjo T, Tanigawa N. 1998. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res 58:5071-5074.
24. Lamprecht SA, Lipkin M. 2003. Chemoprevention of colon cancer by calcium, vitamin D and folate: Molecular mechanisms. Nat Rev Cancer 3:601-614.
25. Li, F, Ling X, Huang H, Brattain L, Apontes P, Wu J, Binderup L, Brattain MG. 2005. Differential regulation of survivin expression and apoptosis by vitamin D3 compounds in two isogenic MCF-7 breast cancer cell sublines. Oncogene 24:1385-1395.
26. Liu SS, Chan KY, Cheung AN, Liao XY, Leung TW, Ngan HY. 2006. Expression of DNp73 and TAp73α independently associated with radiosensitivities and prognoses in cervical squamous cell carcinoma. Clin Cancer Res 12:3922-3927.
27. Lu CD, Altieri DC, Tanigawa N. 1998. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res 58:1808-1818.
28. Ma Y, Yu W-D, Hershberger PA, Flynn G, Kong RX, Trump DL, Johnson CS. 2008. 1a,25-Dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model. Mol Cancer Ther 7:3047-3055.
29. Müller M, Schilling T, Sayan AE, Kairat A, Lorenz K, Schulze-Bergkamen H, Oren M, Koch A, Tannapfel A, Stremmel W, Melino G, Krammer PH. 2005. TAp73/ΔDNp73 influences apoptotic response, chemosensitivity and prognosis in hepatocellular carcinoma. Cell Death Differ 12:1564-1577.
30. Nouraee N, Mowla SJ, Ozhand A, Parvin M, Ziaee SA, Hatefi N. 2009. Expression of survivin and its spliced variants in bladder tumors as potential prognostic marker. Urol J 6:101-108.
31. Novak U, Grob TJ, Baskaynak G, Peters UR, Aebi S, Zwahlen D, Tschan MP, Kreuzer KA, Leibundgut EO, Cajot JF, Tobler A, Fey MF. 2001. Overexpression of the p73 gene is a novel finding in high-risk B-cell chronic lymphocytic leukemia. Ann Oncol 12:981-986.
32. Petrenko O, Zaika A, Moll UM. 2003. DNp73 facilitates cell immortalization and cooperates with oncogenic ras in cellular transformation in vivo. Mol Cell Biol 23:5540-5555.
33. Pozniak CD, Radinovic S, Yang A, McKeon F, Kaplan DR, Miller FD. 2000. An anti-apoptotic role for the p53 family member, p73, during developmental neuron death. Science 289:304-306.
34. Ryan BM, Konecny GE, Kahlert S, Wang HJ, Untch M, Meng G, Pegram MD, Podratz KC, Crown J, Slamon DJ, Duffy MJ. 2006. Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol 17:597-604.
35. Sampath J, Pelus LM. 2007. Alternative splice variants of survivin as potential targets in cancer. Curr Drug Discov Technol 4:174-191.
36. Sarela AI, Scott N, Ramsdale J, Markham AF, Guillou PJ. 2001. Immunohistochemical detection of the anti-apoptosis protein, survivin, predicts survival after curative resection of stage II colorectal carcinomas. Ann surg Oncol 8:305-310.
37. Sherr CJ, Weber JD. 2000. The ARF/p53 pathway. Curr Opin Genet Dev 10:94-99.
38. Span PN, Tjan-Heijnen VCG, Heuvel JJTM, de Kok JB, Foekens JA, Sweep FCGJ. 2006. Do the survivin (BIRC5) splice variants modulate or add to the prognostic value of total surviving in breast cancer? Clin Chem 52:1693-1700.
39. Stiewe T, Theseling CC, Putzer BM. 2002a. Transactivation-deficient Delta TA-p73 inhibits p53 by direct competition for DNA binding: Implications for tumorigenesis. J Biol Chem 277:14177-14185.
40. Stiewe T, Zimmermann S, Frilling A, Esche H, Pützer BM. 2002b. Transactivation-deficient ΔTA-p73 acts as an oncogene. Cancer Res 62:3598-3602.
41. Stiewe T, Stanelle J, Theseling CC, Pollmeier B, Beitzinger M, Pützer BM. 2003. Inactivation of retinoblastoma Rb. tumor suppressor by oncogenic isoforms of the p53 family member p73. J Biol Chem 278:14230-14236.
42. Stiewe T, Tuve S, Peter M, Tannapfel A, Elmaagacli AH, Pützer BM. 2004. Quantitative TP73 transcript analysis in hepatocellular carcinomas. Clin Cancer Res 10:626-633.
43. Trump DL, Hershberger PA, Bernardi RJ, Ahmed S, Muindi J, Fakih M, Yu WD, Johnson CS. 2004. Anti-tumor activity of calcitriol: Pre-clinical and clinical studies. J Steroid Biochem Mol Biol 89-90:519-526.
44. Tuve S, Wagner SN, Schittek B, Pützer BM. 2004. Alterations of DTA-p73 splice transcripts during melanoma development and progression. Int J Cancer 108:162-166.
45. Uramoto H, Sugio K, Oyama T, Nakata S, Ono K, Morita M, Funa K, Yasumoto K. 2004. Expression of deltaNp73 predicts prognosis in lung cancer. Clin Cancer Res 10:6905-6911.
46. Wager M, Guilhot J, Blanc JL, Ferrand S, Milin S, Bataille B, Lapierre F, Denis S, Chantereau T, Larsen CJ, Karayan-Tapon L. 2006. Prognostic value of increase in transcript levels of Tp73 DeltaEx2-3 isoforms in low-grade glioma patients. Br J Cancer 95:1062-1069.
47. Wang Z, Fukuda S, Pelus L. 2004. Survivin regulates the p53 tumor suppressor gene family. Oncogene 23:8146-8153.
48. Zaika AI, Slade N, Erster SH, Sansome C, Joseph TW, Pearl M, Chalas E, Moll UM. 2002. DNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors. J Exp Med 196:765-780.